Global CAR-T Cell Therapies: 2022 Intellectual Property Landscape Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “CAR-T Cell Therapies: Intellectual Property Landscape)” report has been added to ResearchAndMarkets.com’s offering.

This report features an extensive study of the historical and current collection of granted patents, patent applications and affiliated documents associated with the upcoming suite of programmable, personalized anticancer therapies.

The information in this report has been presented across two deliverables, namely a MS Excel sheet, featuring an interactive dashboard, and an MS PowerPoint presentation, summarizing the ongoing activity in this domain, and key insights drawn from the available data.

Cancer, one of the leading causes of death worldwide, claimed close to 10 million lives annually Although there are several treatment options available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is difficult to achieve. In this context, immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise.

For instance, after multiple rounds of chemotherapy, a stem cell transplant, participating in two clinical trials of experimental anticancer interventions and targeted radiation therapy, Scott McIntyre was treated with a CAR T-cell therapy at the University of Chicago Medicine, in 2016. Till date, he is in complete remission from his diffuse large B-cell lymphoma (DLBCL).

This highly specific and promising form of treatment that harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment across the world. CAR-T therapies have so far been evaluated and approved for several hematological malignancies; ABECMA (relapsed or refractory multiple myeloma), BREYANZI (relapsed or refractory large B-cell lymphoma), TECARTUST (relapsed or refractory B-cell precursor ALL), KYMRIAHT (relapsed or refractory DLBCL and relapsed or refractory ALL), YESCARTAT (DLBCL, primary mediastinal B-cell lymphoma, high grade B-cell lymphoma, and follicular lymphoma), are products involving the use of CAR-T cells, which have been approved by the US FDA.

Presently, the success rate for CAR T-cell therapies is estimated to be around 30% to 40%, offering lasting remission without requiring any additional treatments. Cytokine release syndrome (CRS), a commonly reported side effect of the treatment, is typically observed within a few days to a couple of weeks after CAR T-cell infusion. In severe cases, patients with CRS may need to be transferred to intensive care and even require life-support machines to stay alive.

However, over time, medical science has developed the necessary means to control / treat CRS. In addition, a successful CAR-T cell graft is known to cause certain rare types of infections, which are generally observed in severely immunodeficient patients. This is because the programmed, effector T-cells also eliminate normal immune cells, which are responsible for keeping infections at bay, in a healthy host.

Other barriers to therapeutic success include inadequate anti-tumor activity (in certain cases), antigen escape, restricted trafficking, and limited tumor infiltration. As a result, there is a lot happening in terms of innovation related to this promising segment of cell-based therapies; medical researchers are developing targeted interventions for different indications and also exploring ways to make the therapy safer. It is also worth mentioning that a lot of capital has also been invested to support R&D activity in this burgeoning field of research. This report attempts to identify key trends that describe the pace and focus of innovation related to CAR-T cell therapies, and make key observations / inferences regarding the development of intellectual capital in this domain.

Scope of the Report

The report features the following details:

• Overall Intellectual Property Landscape
• Popular / Relevant Prior Art Search Expressions
• Patent Valuation Analysis
• Patentability and Freedom to Operate
• Analysis of Patent Applications
• Analysis of Granted Patents
• Pockets of Innovation and White Spaces
• Claims Analysis

Key Topics Covered:

Excel Deliverable

1. Research Notes

2. Summary Dashboard

3. Overall Intellectual Property Landscape Dataset

4. Prior Art Search Expressions (Keyword Analysis)

5. Patent Applications Dataset

6. Granted Patents Dataset

7. Claims Analysis

8. Key Applicants Analysis

9. CPC Analysis

10. Appendix I: Pivot Tables

11. Appendix II: Country / Geography Codes

12. Appendix III: Innovation Categories

PowerPoint Deliverable

1. Context

2. Project Approach

3. Project Objectives

4. Executive Summary

5. CAR-T cell therapies

6. Overall Intellectual Property Landscape

7. Key Prior Art Search Expressions

8. Intellectual Property Valuation Analysis

9. Analysis of Patent Applications

10. Analysis of Granted Patents

11. Key Applicants

11.1. Overview

11.2. Analysis of Key Applicants

11.2.1. University of Pennsylvania

11.2.2. Juno Therapeutics

11.2.3. Cellectis

11.2.4. University of California

11.2.5. bluebird bio

11.2.6. Memorial Sloan Kettering Cancer Center

11.2.7. Novartis

11.2.8. Baylor College of Medicine

11.2.9. Kite Pharma

11.2.10. University of Texas

12. Pockets of Innovation and White Spaces

13. Future Outlook

14. Appendices

For more information about this report visit https://www.researchandmarkets.com/r/i5li5j

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900